Rubicon Research Limited (NSE:RUBICON)
India · Delayed Price · Currency is INR 772.25
-8.45 (-1.08%)
At close: Feb 12, 2026
Rubicon Research Revenue
Rubicon Research had revenue of 4.76B INR in the quarter ending December 31, 2025, with 60.65% growth. This brings the company's revenue in the last twelve months to 15.98B. In the fiscal year ending March 31, 2025, Rubicon Research had annual revenue of 12.84B with 50.40% growth.
Revenue (ttm)
15.98B
Revenue Growth
+50.40%
P/S Ratio
7.96
Revenue / Employee
17.70M
Employees
903
Market Cap
127.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 12.84B | 4.30B | 50.40% |
| Mar 31, 2024 | 8.54B | 4.60B | 116.99% |
| Mar 31, 2023 | 3.94B | 799.52M | 25.50% |
| Mar 31, 2022 | 3.14B | -11.49M | -0.37% |
| Mar 31, 2021 | 3.15B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 79.18B |
| Granules India | 50.92B |
| J. B. Chemicals & Pharmaceuticals | 41.93B |
| GlaxoSmithKline Pharmaceuticals | 37.09B |
| Caplin Point Laboratories | 20.92B |
| FDC Limited | 20.78B |
| AstraZeneca Pharma India | 20.06B |
| Sanofi India | 19.33B |